A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)

Phase 3

Completed

• Conditions: Wet Age-related Macular Degeneration
• Interventions: Drug: Aflibercept

• Registration Number: NCT05345236
• Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Brief Summary

This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy and safety of QL1207 compared to Eylea® in subjects with wet AMD.

Detailed Description

Subjects will be randomised in a 1:1 ratio to receive either QL1207 or Eylea® (administered via intravitreal \[IVT\] injection 2 mg \[0.05 mL\] every 4 weeks for the first 3 months (i.e., at Weeks 0, 4, and 8), followed by 2 mg \[0.05 mL\] once every 8 weeks ) . Subjects will be administered the study drug up to week 48, and the last assessment will be done at Week 52.

Study Timeline

• Study Start: 2019-08-19
• Primary Completion: 2022-01-25
• Study Completion: 2022-01-25
• Status Verified: 2022-04
• Study First Submitted: 2022-04-19
• Study First Submitted QC: 2022-04-19
• Last Update Submitted: 2022-04-19
• Study First Posted: 2022-04-25
• Last Update Posted: 2022-04-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 366

Inclusion Criteria

1. Age ≥ 50 years male and female
2. Treatment naïve, *active subfoveal choroidal neovascularisation (CNV) lesion secondary to AMD in the study eye
3. CNV area ≥50% of total lesion size
4. Total lesion area ≤ 12.0 Disc Areas (DA) in size (including blood, scars, and neovascularisation) in the study eye
5. BCVA of 20/40 to 20/200 (letter score of 73 to 34, inclusive) using ETDRS charts in the study eye
6. Fellow eye is not expected to need any anti-VEGF treatment for the duration of study participation.

Exclusion Criteria

Study eye:

1. Sub- or intra-retinal haemorrhage that comprises more than 50% of the entire lesion or presence of blood with the size of 1 DA or more involving the centre of fovea

2. Scar, fibrosis, or atrophy involving the centre of the fovea

3. Presence of CNV due to other causes, such as ocular histoplasmosis, trauma, multifocal choroiditis, angioid streaks, history of choroidal rupture, or pathologic myopia

4. Any concurrent macular abnormality other than AMD which could affect central vision or the efficacy of IP

5. Current vitreous haemorrhage within 30days before randomization

6. Any other intraocular surgery or periocular surgery within 90 days prior to randomisation, except for lid surgery, which may not have taken place within 30 days prior to randomisation.

7. Uncontrolled ocular hypertension (defined as intraocular pressure [IOP] ≥ 25 mmHg despite treatment with anti-glaucoma medication) at Screening

   Either eye:

8. Any previous IVT anti-vascular endothelial growth factor (VEGF) treatment

9. Any previous systemic anti-VEGF treatment

10. History of treatment involving macula such as macular laser photocoagulation, photodynamic therapy (PDT), transpupillary thermotherapy (TTT), radiation therapy, or any ocular treatment for neovascular AMD

11. Active or suspected ocular and periocular infection at Screening or at randomisation

12. History of idiopathic or autoimmune-associated uveitis

    Other:

13. Known allergic reactions and/or hypersensitivity to any component of Eylea or QL1207 or allergy to the fluorescein sodium for injection in angiography

14. Uncontrolled systemic hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 95 mmHg on optimal medical regimen)

15. Any previous systemic anti-VEGF treatment

16. Women of childbearing potential who are pregnant, planning to become pregnant, lactating, or not using adequate birth control, as specified in protocol. For women of childbearing potential, a serum pregnancy test must result negative at Screening.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
QL1207	Aflibercept	Subjects randomized into QL1207 group will receive QL1207 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.
Eylea®	Aflibercept	Subjects randomized into Eylea® group will receive Eylea® 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.

Primary Outcome Measures

Name	Time	Method
Best-Corrected Visual Acuity (BCVA) Change From Baseline (No. of Letters) to Week 12	Baseline (Day 0), Week 12

Secondary Outcome Measures

Name	Time	Method
Change from baseline in CNV area from baseline to week 12, week 24 and week 52	Baseline (Day 0), Week 12, Week 24, Week 52
Change From Baseline in CRT(central retina thickness) by visit	Baseline (Day 0), week 4, week 8, Week 12, Week 24, Week 52
BCVA Change From Baseline by visit	Baseline (Day 0), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52
Proportion of subjects who gained at least 5,10 and 15 lettersbaseline to week 12,week 24 and week 52	Baseline (Day 0), Week 12, Week 24, Week 52

Trial Locations

Locations (1)

Peking Union Medical College Hospital; 🇨🇳 Beijing, Beijing, China